Grants per year
Personal profile
Research Interests
The elucidation of eukaryotic signal transduction pathways, the study of signal transduction pathway perturbation in disease or injury, and the utilization of this knowledgebase for rational drug discovery and development.
Training Experience
| 1977 | Postdoctoral Fellowship, Duke University |
Education/Academic qualification
PhD, Emory University
… → 1975
Research interests
- Alzheimer's Drug
- Biochemistry: Proteins
- Brain Cancer / Nervous System Cancer
- Brain Injury
- Drug Discovery
- Neuroinflammation
- Pharmacology
- Signal Transduction
Fingerprint
Dive into the research topics where Daniel Martin Watterson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 8 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
-
CardioExcyte 96 System for Pharmacology Research at Northwestern University
Abdulkadir, S. A., Ardehali, H., Arora, R. K., Burridge, P., George Jr., A. L., Kearney, J. A., McNally, E. M., Schiltz, G. E., Watterson, D. M., Wilsbacher, L. D. & Silverman, R. B.
Office of the Director, National Institutes of Health
6/15/20 → 6/14/21
Project: Research project
-
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
Anderson, W. F. & Watterson, D. M.
5/15/20 → 4/30/24
Project: Research project
Research Output
-
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers
Van Eldik, L. J., Sawaki, L., Bowen, K., Laskowitz, D. T., Noveck, R. J., Hauser, B., Jordan, L., Spears, T. G., Wu, H., Watt, K., Raja, S., Roy, S. M., Watterson, D. M. & Guptill, J. T., Feb 2021, In: Clinical Pharmacology in Drug Development. 10, 2, p. 131-143 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Erratum: A selective and brain penetrant p38αMAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction (J. Med. Chem. (2019) 62:11 (5298-5311) DOI: 10.1021/acs.jmedchem.9b00058)
Roy, S. M., Minasov, G., Arancio, O., Chico, L. W., van Eldik, L. J., Anderson, W. F., Pelletier, J. C. & Martin Watterson, D., Aug 13 2020, In: Journal of Medicinal Chemistry. 63, 15, p. 8649 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Involvement of p38 mapk in synaptic function and dysfunction
Falcicchia, C., Tozzi, F., Arancio, O., Watterson, D. M. & Origlia, N., Aug 2 2020, In: International journal of molecular sciences. 21, 16, p. 1-14 14 p., 5624.Research output: Contribution to journal › Review article › peer-review
Open Access5 Scopus citations -
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
Roy, S. M., Minasov, G., Arancio, O., Chico, L. W., Van Eldik, L. J., Anderson, W. F., Pelletier, J. C. & Watterson, D. M., Jun 13 2019, In: Journal of Medicinal Chemistry. 62, 11, p. 5298-5311 14 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia
Braun, D. J., Bachstetter, A. D., Sudduth, T. L., Wilcock, D. M., Watterson, D. M. & Van Eldik, L. J., Oct 1 2019, In: GeroScience. 41, 5, p. 671-679 9 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations